Fengling Li

This study introduces E-ASMS, a method to detect weak binders and assess enantioselectivity, identifying 16 binders across 12 human protein targets with confirmed binding mechanisms.

The paper identifies UNC10013, a covalent ligand targeting SETDB1's 3TD domain, which reduces methyltransferase activity and shows selectivity in cells.

This study develops a bioluminescence-based assay to kinetically characterize three human RNA helicases and establishes a high-throughput method for inhibitor discovery.

This paper describes a targeted protein degradation strategy using UNC8732 to recruit FBXO22 for NSD2 degradation, leading to growth suppression and reversal of drug resistance in leukemia cells.

This study identifies epigenetic vulnerabilities in AML and MDS/MPN with EZH2 mutations, showing increased sensitivity to EZH2 and EED inhibitors and upregulation of cell death pathways.

The paper develops improved GRABDA sensors to monitor dopaminergic activity in vivo, showing high sensitivity and spatially resolved DA release in mice during behaviors.

The paper shows that (R,R)-59, a SETDB1 ligand, enhances SETDB1-mediated methylation of Akt1 and promotes cell proliferation.

This study shows that inhibiting SUV4-20 H1 increases frataxin expression in FRDA cells and patient-derived cells, suggesting it as a therapeutic target.